The functional and structural characterization of a novel oncogene GIG47 involved in the breast tumorigenesis by Kyou-Hoon Han et al.
Han et al. BMC Cancer 2012, 12:274
http://www.biomedcentral.com/1471-2407/12/274RESEARCH ARTICLE Open AccessThe functional and structural characterization of a
novel oncogene GIG47 involved in the breast
tumorigenesis
Kyou-Hoon Han1†, Si-Hyung Lee1†, Seon-Ah Ha2†, Hyun Kee Kim2†, CheWook Lee1, Do-Hyoung Kim1,
Kee Hwan Gong2, JinAh Yoo2, Sanghee Kim2 and Jin Woo Kim2,3*Abstract
Background: A candidate oncogene GIG47, previously known as a neudesin with a neurotrophic activity, was
identified by applying the differential expression analysis method.
Methods: As a first step to understand the molecular role of GIG47, we analyzed the expression profile of GIG47 in
multiple human cancers including the breast cancer and characterized its function related to human
carcinogenesis. Based on this oncogenic role of GIG47, we then embarked on determining the high-resolution
structure of GIG47. We have applied multidimensional heteronuclear NMR methods to GIG47.
Results: GIG47 was over-expressed in primary breast tumors as well as other human tumors including carcinomas
of the uterine cervix, malignant lymphoma, colon, lung, skin, and leukemia. To establish its role in the pathogenesis
of breast cancer in humans, we generated stable transfectants of MCF7 cells. The ectopic expression of GIG47 in
MCF7 cells promoted the invasiveness in the presence of 50% serum. In addition, it also resulted in the increased
tumorigenicity in in vivo tumor formation assay. The tumorigenesis mechanism involving GIG47 might be mediated
by the activation of MAPK and PI3K pathways. These results indicate that GIG47 plays a role in the breast
tumorigenesis, thus representing a novel target for the treatment of breast cancer. To facilitate the development of
GIG47-targeted therapeutics, we determined the structural configuration of GIG47. The high-resolution structure of
GIG47 was obtained by combination of NMR and homology modeling. The overall structure of GIG47 has four
α-helices and 6 β-strands, arranged in a β1-α1-β2-β3-α2-β4-α3-α4-β5-β6 topology. There is a potential heme/steroid
binding pocket formed between two helices α2 and α3.
Conclusion: The determined three-dimensional structure of GIG47 may facilitate the development of potential
anti-cancer agents.
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Breast cancer is nowadays the most frequent malignant
tumor in female, and morbidity and mortality continue
to increase [1]. Despite advances in early detection and
the understanding of the molecular bases of breast can-
cer biology, about 30% of patients with early-stage breast* Correspondence: jinwoo@catholic.ac.kr
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reproduction in any medium, provided the orcancer have recurrent disease. Furthermore, the course
of the disease and response to treatment vary greatly [2].
In view of the heterogeneity of breast carcinomas, the
need for reliable diagnostic or therapeutic markers is ob-
vious in terms of both their biological profile and their
clinical outcome.
The identification of molecular alterations in can-
cerous and pre-cancerous cells has provided insight
into the role of oncogenes and tumor suppressor
genes in tumor initiation and progression [3]. Onco-
genes are derived from highly conserved protoonco-
genes that are altered by chromosomal point mutations,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nal transduction pathways subverted by oncoproteins
govern fundamental cell functions, including prolifera-
tion, cell cycle regulation, and apoptosis [5]. Thus, the
structural and functional characterization of oncopro-
teins underlying cancer will aid in developing the diag-
nostic and therapeutic avenues.
We measured gene expression levels in a series of
breast normal and tumor primary tissues to discover
genes involved in tumorigenesis of human breast tissue,
and isolated the new human breast cancer-related gene,
GIG47 (GenBank accession number AY762102). GIG47
corresponds to Homo sapiens neuron derived neuro-
trophic factor (NENF) (GenBank accession number
NM_013349), which encodes a neurotrophic factor
involved in neuron differentiation and development in
mice [6,7]. Mouse neudesin is a secreted protein with
neurotrophic activity in neurons and undifferentiated
neural cells [6,7]. It exhibited a high similarity (∼90%
identity) to human and rat neudesins. The neurotrophic
activity of neudesin was mediated through the activation
of mitogen-activated protein (MAP) [8] and phosphati-
dylinositol 3-kinase (PI-3 K) [9] pathways.
There are also previous reports on the functional as-
pect of GIG47 related to the tumorigeneis. Accord-
ing to these groups, GIG47 mRNA was up-regulated
in immortalized cells [10]. In agreement with this, the
breast cancer proteomics approach demonstrated that
GIG47 protein was abundant in estrogen receptor
(ER)+/progesterone receptor (PR) + breast cancers [11].
In spite of this previous research on GIG47 related to
human cancer, its molecular function remains to be
discovered.
As a first step to understand the molecular role of
GIG47, we analyzed the expression profile of GIG47 in
multiple human cancers including the breast cancer.
This result revealed that GIG47 is highly up-regulated in
most of human cancers. In addition, the ectopic expres-
sion of GIG47 promoted the invasiveness and tumori-
genesis of breast cancer cells. Based on this oncogenic
role of GIG47, we then embarked on determining the
high-resolution structure of GIG47. Bioinformatics pre-
dictions and preliminary circular dichroism spectropo-
larimetry data indicated that GIG47 might belong to the
family of intrinsically unfolded proteins (IUPs) with
~50% of its amino acid residues not participating in
forming secondary and/or tertiary structure. As IUPs do
not produce suitable single crystals for structural study
by x-ray crystallography, we have applied multidimen-
sional heteronuclear NMR methods to GIG47 that are
currently best suited for characterizing structural fea-
tures of IUPs [12-14].
The purpose of our study was to identify an unique
gene that shows cancer-associated expression, tocharacterize its function related to human carcinogen-
esis, and to determine its three-dimensional structure.
Methods
Tissues and cell lines
For differential display of mRNA, normal and neoplastic
breast tissue specimens were obtained from the surgical
services of Gangnam St. Mary’s Hospital, The Catholic
University of Korea (Seoul, Korea). Patient written con-
sents were obtained from each individual and the use of
tissue samples was approved by the ethics committee of
our institution (Catholic ethics committee). Mammalian
cell lines described below were all obtained from the
American Type Culture Collection (Manassas, VA):
MCF-7 and MDA-MB-231 cells are human breast
adenocarcinoma. MCF-7 cell line was cultured in Eagle’s
Minimum Essential Medium supplemented with 10%
FBS and bovine insulin (0.01 mg/ml). MDA-MB-231 cell
line was cultured in Leibovitz’s L-15 medium supple-
mented with 10% FBS.
Differential display reverse transcription-PCR (DDRT-PCR)
Total RNA was extracted from tissues with an RNA ex-
traction kit (RNeasy total RNA kit, Qiagen Inc., Valencia,
CA), and 0.2 μg of total RNA were used to generate
cDNA in a reverse transcription reaction (RNAimage
kit, GenHunter, Nashville, TN). With the use of the dif-
ferential display kit (RNAimage kit), we performed PCR
with oligo-dT primers and arbitrary sequences, each 13
bases in length according to the manufacturer’s recom-
mendations. After cDNA of mRNAs was generated, the
PCR products were separated by electrophoresis on a
6% denaturing polyacrylamide gel. The cDNA was then
reamplified without [α-35 S]dATP and with 20 μM de-
oxynucleotide triphosphates instead of 2 μM deoxynu-
cleotide triphosphates. From the films, a 206-bp cDNA
(referred to as HP73) was identified by the use of 5’-
arbitrary primer H-AP21 (5’-AAGCTTTCTCTGG-30) and
3’H-T11C anchored primer (5’-AAGCTTTTTTTTTTTC-
3’; GenHunter). HP73 was then subcloned into the pGEM-
T easy vector with the use of the TA cloning system and
sequenced to an automatic sequencing analysis [15,16].
cDNA library screening
To isolate the full-length cDNA clone that contained the
partial HP73 sequence, a bacteriophage λgt11 human
lung embryonic fibroblast cDNA library was screened by
plaque hybridization with 32P-labeled HP73 partial
cDNA probe.
Construction of expression vector, DNA transfection, and
western blotting
To generate an eukaryotic expression construct of GIG47,
we amplified the coding region of GIG47 by PCR, which
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Directional TOPO expression kit, Invitrogen) according
to the manufacturer’s recommendations. To express
GIG47 in MCF7 cells, we seeded 3x105 cells per 60-mm
tissue culture dish (Costar, Cambridge, MA). The next
day, the cells were transfected with 10 μl of Lipo-
fectamine 2000 reagent (Invitrogen, CA) and 5 μg of
GIG47/pcDNA3.1 and pcDNA3.1 vector alone. After a
10-h incubation, the cells were cultured in media sup-
plemented with 10% FBS.
For Western blot analysis, cells were lysed in a lysis
buffer [20 mM Tris (pH 7.4), 1% NP40, 5 mM EDTA,
10% glycerol, 0.1% SDS, and 150 mM NaCl] containing
protease inhibitor mixture (Sigma, St. Louis, MO). The
cell lysates containing 20 μg of total protein were loaded
on 10% SDS-polyacrylamide gels and separated by elec-
trophoresis. Protein samples were then transferred to
nitrocellulose membranes. The blots were incubated
with polyclonal anti-V5 antibody (Invitrogen) and devel-
oped with the enhanced chemiluminescence detection
kit (Amersham Pharmacia Biotech., Uppsala, Sweden).
Northern blot analyses
Total RNA was extracted from frozen human tissues
with TRIzol reagent (Invitrogen). Northern blot analysis
were carried out in which 20 μg of denatured total RNA
were electrophoresed on a 1.0% formaldehyde agarose
gel and transferred to a nylon membrane (Roche Diag-
nostics GmbH, Mannheim, Germany). The mRNA ex-
pression of GIG47 was also assessed in normal human
tissues and a variety of human cancer cell lines with the
use of membrane commercially available from Clontech
(Palo Alto, CA), which was processed as recommended
by the supplier. Human β-actin cDNA control probe
provided by Clontech was used as a loading control. All
blots were hybridized with the randomly primed [32P]-
labeled GIG47 partial cDNA probe (the HP73 fragment).
Quantitative RT-PCR analysis
Total RNA was extracted from different cell lines and
normal breast tissues using the RNAeasy minikit (Qia-
gen). The quality of the RNA was determined on agarose
gel electrophoresis. After the spectrometric analysis,
equal amounts of RNA were used for cDNA synthesis.
After DNase treatment, oligo dT primers were used for
first-strand cDNA synthesis. All procedures were per-
formed according to the manufacturer’s instruction
(Invitrogen). Quantitative PCR was performed on the
CFX96 Real-time PCR Detection System using iQ Syber-
Green supermix according to instructions and analyzed
by software (all Bio-Rad Laboratories, CA). The primers
were designed by BEACON DESIGNER (v7.5; Premier
Biosoft International). Sequences were as follows: GIG47




Invasion assays were done using the Cell Invasion Assay
kit (Chemicon International, Inc., CA). Briefly, cells
(5,000/ml) were maintained in serum-free medium with
or without 50% FBS as a chemoattractant at 37 °C for 24
hours. Invaded cells were subsequently detached, lysed,
and detected by CyQuant GR dye using fluorescence
plate reader Mithras LB 940 (Berthold Technologies,
Germany).
Tumorigenicity assay
5-week-old athymic nude mice (4–8 per group) were
injected s.c. with 106 MCF7-GIG47 and MCF7-pcDNA3
.1 cells into axillary mammary fat pads. Tumors were
measured weekly and tumor areas were calculated as 1/4
x length x width x π. The data is reported as mean
tumor area per group.
Protein purification
In order to express and purify GIG47, we have sub-
cloned the synthesized GIG47 gene into a V3 expression
vector, using Nhe I (GCTAGC) and Xho I (CTCGAG).
Also, to enhance the solubility for facile purification of
GIG47 and for sample preparation for NMR measure-
ments we added his-tags to both N- and C- termini with
the sequences of MHHHHHHSSGLVPRGSGMKETAA-
AKFERQHMDSPDLGTDDDDKAMASGG and GGGL-
EHHHHHH, respectively. Transformed Escherchia coli
BL21(DE3) cells were grown at 37 °C to an OD600 of 0.6
and the culture was induced with 0.5 mM isopropyl
thio-β-D-thiogalactopyranoside (IPTG). Then, the cells
were further cultivated at 20 °C for 16 hours. The har-
vested cell suspension was sonicated in 20 mM Tris–
HCl (pH 8), 0.5 M NaCl, 1 mM PMSF, 20 mM imidazole
and centrifuged for 30 minutes at 30,000 × g. Both
unlabeled and 13 C/15N-labeled GIG47 were purified,
using Ni-Sepharose column, Q-Sepharose column, SP-
Sepharose column, and Hiprep 26/60 Sephacryl S-200
FPLC column (GE Healthcare). The molecular weight of
the purified protein was confirmed by MALDI-TOF
mass spectrometry.
NMR spectroscopy
NMR spectra were acquired using a Varian Unity
INOVA 600 and Bruker Avance II 900 spectrometers
equipped with cryogenic probes. For backbone assign-
ment of the GIG47, 15N-1H HSQC, gnoesyNhsqc, gtoc-
syNhsqc, HNCACB, CBCACONNH, HNCO, HNCA,
CCC-TOCSY, and HNCACO spectra were obtained at
30 °C in 20 mM sodium acetate-d3 (pH 6.5), 0.01 mM
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dine, 0.02% (w/v) NaN3, 90% H2O/10%
2H2O. The Cα
CSI values were obtained based on the method of
Wishart and Sykes [17-19]. All data were processed and
analyzed using a Varian Vnmr software and an nmrPipe/
nmrDraw software.
CD spectropolarimetry
A CD spectrum was obtained with a 20 μM protein
sample on a JASCO J-720 spectropolarimeter using a
1 mm cell in 20 mM sodium acetate (pH 6.5), 0.1 mM
PMSF, 0.01 mM EDTA, 1 mM DTT, 0.1 mM benzami-
dine, 0.02% (w/v) NaN3 at 20 °C.
Homology modeling
The high-resolution three-dimensional structure of
GIG47 was determined by a homology modeling proced-
ure MODELLER using 1TOG as a template according to
a published protocol [20]. 1TOG is a hypothetical pro-
tein At2g24940.1 found Arabidopsis thaliana (BMRB id:
bmrb 6138) whose function is unknown [21]. Since the
sequence homology between the two proteins is ~ 49%
(outside the twilight zone) calculating the structure of
GIG47 by homology modeling is a reasonable strategy.
Results
Cloning of GIG47 over-expressed in the breast cancer and
GIG47 gene expressions in human cancers
To discover genes critical for the breast tumorigenesis,
we analyzed the differential gene expression profile by
applying a differential display technique. Total RNAs
were isolated from the normal breast tissues, the breast
cancer tissue, and the breast cancer cell line (MCF-7).
Partial cDNA synthesized from them was resolved on
acrylamide gel and excised from the gel based on their
cancer-associated expressions. We then identified the
206-bp partial cDNA fragment named HP73 that was
over-expressed in breast cancer tissues and MCF-7 cells
but not in normal breast tissue (Figure 1A). Using the
partial cDNA HP73 as a probe, we next screened human
lung embryonic fibroblast cDNA library to isolate the
full-length cDNA. One clone with a size of 703-bp
named GIG47 (GenBank accession number AY762102)
was isolated. Sequence analysis showed that this cDNA
encodes NENF gene (GenBank accession number
NM_013349) with a molecular weight of ~ 19 kDa.
To characterize its expression profile related to the
breast cancer, we performed the quantitative PCR ana-
lysis in breast normal tissues and several breast cancer
cell lines. As consistent with the result in Figure 1A, its
expression was highly elevated in all breast cancer cell
lines examined here compared to normal breast tissues
(Figure 1B).To assess whether our findings obtained from analyz-
ing the breast cancer cells have physiological and clinical
relevance, we examined GIG47 expression in tissue sam-
ples derived from primary breast cancers. The expres-
sion of GIG47 mRNA in breast tumor tissues was
analyzed by Northern blotting on a breast normal and
tumor tissue blot. We then observed that GIG47 mRNA
level is highly up-regulated in the breast tumors com-
pared to the normal breast tissue (Figure 1C). Therefore,
our result suggests that GIG47 over-expressed in human
breast cancer might play an important role in the breast
tumorigenesis.
Northern hybridization was performed on a human
normal multiple tissue mRNA blot and a human cancer
cell line mRNA blot to analyze the GIG47 expressions in
various normal tissues and cancer cell lines. The GIG47
mRNA (~ 1.0 Kb) was weakly expressed in many normal
tissues, including the brain, skeletal muscle, colon, thy-
mus, spleen, kidney, liver, small intestine, placenta, lung
and leukocyte except normal heart in which GIG47 tran-
script was strongly expressed (Figure 1D). In contrast,
its level was detected at a very high level in several can-
cer cell lines such as the promyelocytic leukemia cell line
HL-60, cervical cancer cell line HeLa, a chronic myelo-
genous leukemia cell line K562, lymphoblastic leukemia
cell line MOLT-4, Burkitt’s lymphoma cell line Raji,
colon cancer cell line SW480, lung cancer cell line A549,
and melanoma cell line G361 (Figure 1E). Thus, North-
ern blot analyses show that GIG47 mRNA exists abun-
dantly in many cancer cell lines compared with its little
or no expression in most normal tissues. This suggests
that the functional role of GIG47 is required for various
cancer cell types derived from different organs. We also
added the expression profile of normal cell lines
(Figure 1E). The normal cell lines included here are BJ,
IMR-90, and MCF12F which are a human fibroblast
from normal foreskin, a human lung cell fibroblast, and
an epithelial cell line from normal mammary gland, re-
spectively. As shown in the Figure 1E, the expression
levels of GIG47 in human normal cell lines were rela-
tively low.
Ectopic expression of GIG47 results in the increased
tumorigenecity
As previously reported [6], GIG47 was a secreted protein
mostly expressed in the extracellular supernatant of cells
(Figure 2A). To investigate the role of GIG47 in breast
cancer, we stably transfected MCF7 cells with pcDNA3.1
and pcDNA3.1-GIG47 constructs, and selected three
clones with high steady-state levels of GIG47 (G3, G4,
and G7). Western blot analysis showed the bands of
expected molecular weight in the cell extracts from
MCF7-GIG47 clones but not from vector controls and
parental cell types (Figure 2B).
Figure 1 Identification of GIG47 and its expression patterns in human breast cancers, multiple human tissues and cancer cell lines. (A)
Comparative gene expression profile examined by DDRT-PCR using total RNA isolated from normal breast tissue, breast cancer tissue, and MCF-7
breast cancer cell line. Differential display was carried out 5' arbitrary primer H-AP21 (5’-AAGCTTTCTCTGG-3’) and 3’ H-T11C anchored primer
(5’-AAGCTTTTTTTTTTTC-3’; GenHunter). The PCR products were resolved by electrophoresis. HP73 is the name of the partial GIG47 gene product.
The arrow identifies the location relative to other PCR products. (B) The expression level of GIG47 was examined by the quantitative PCR analysis
in various breast cancer cell lines compared to the normal breast tissues. (C) Total RNAs were isolated from normal breast tissues and their
corresponding primary breast cancer tissues. Blot was hybridized with the randomly primed [32P]-labeled GIG47 partial cDNA probe (the HP73
fragment). Human β-actin cDNA was used as a control probe (lower panel). Northern blotting was performed to determine the expression of
GIG47 in different human tissues. Normal 12 lane multiple tissue northern blot (D) or human cancer cell line multiple northern-blot (E) purchased
from Clontech were probed with a radioactively labeled HP73 partial cDNA (upper panel) or human β-actin cDNA control probe provided by
Clontech (lower panel). (E) The normal cell lines included here were BJ, IMR-90, and MCF12F which are a human fibroblast from normal foreskin,
a human lung cell fibroblast, and an epithelial cell line from normal mammary gland, respectively.
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presence of chemoattractant (50% FBS) showed signifi-
cantly increased invasiveness almost reaching the level
of MDA-MB-231 cells used as a positive control whereas
the invasiveness of MCF7 cells stably transfected with
the vector alone remained low. All three MCF7-GIG47
clones showed the increased invasiveness compared to
MCF7 control cells (Figure 2C).
To test the effect of GIG47 over-expression on
tumorigenicity, two GIG47-over-expressing MCF7
clones (G3 and G7) as well as MCF7 cells stably trans-
fected with pcDNA3.1 vector were bilaterally injected
into the mammary fat pads of athymic nude mice. Both
GIG47-overexpressing MCF7 clones showed increased
tumor growth rate compared with MCF7 vector control
(Figure 2D). Especially at week 8, tumors formed by
MCF7-GIG47 cells were clearly larger than in the con-
trol group. Therefore, our result indicates that GIG47over-expressed in multiple human cancers indeed serves
to mediate the tumorigenesis in breast cancer.
We also perform the experiments to suggest the im-
portant function of GIG47 related to the tumorigenesis.
To do this, we induced the over-expression of GIG47 in
NIH/3 T3, a normal murine fibroblast cell line. We then
tested its tumorigenecity with the proliferation and
in vivo tumorigenecity assays. As shown in Figure 2E,
the results show that the cell growth rate of NIH/3 T3 is
significantly increased compared to control cells. In
addition, the clonal population of NIH/3 T3 cells over-
expressing GIG47 was bilaterally injected into the mam-
mary fat pads of athymic nude mice together with
NIH3T3 cells carrying the empty vector. We then
assessed its tumor growth rate. The results showed that
GIG47-overexpressing NIH/3 T3 clones exhibit the
increased tumor growth rate compared with NIH/3 T3
cells vector control (Figure 2F). Especially at day 30,
Figure 2 Increased invasiveness and tumorigenicity of MCF7 stable cell lines over-expressing GIG47. (A) MCF7 cells were transiently
transfected with GIG47/pcDNA3.1 construct, and the cell pellet and culture media were separated by centrifugation. The cell pellet was lysed by a
lysis buffer while culture media was concentrated. The GIG47 protein expression was analyzed by Western blot analysis with anti-V5 antibodies.
Lane 1 and 2 are the cell lysate and concentrated culture media, respectively. (B) Western blot analysis of GIG47 protein levels in established
MCF7 stable cell lines. (C) Effect of GIG47 over-expression in in vitro invasion of MCF7 cells. Invasion analysis of three clones was performed in
serum-rich medium (50% FBS). Experiments were repeated at least three times. MDA-MB-231 cells were used as a positive control. (D) Increased
tumorigenicity of GIG47 over-expressing MCF7 cells. MCF7-GIG47 clones (G3 and G7) and MCF7-pcDNA3.1 cells were inoculated into mammary
fat pads of athymic nude mice. The tumor growth was measured every week after the inoculation. (E) The cell growth rate of NIH/3 T3
overexpressing GIG47 was significantly increased compared to control cells. (F) GIG47-overexpressing NIH/3 T3 clones exhibited the increased
tumor growth rate compared with NIH/3 T3 cells vector control.
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ger than in the control group. Therefore, these two add-
itional experiments strongly support our conclusion that
GIG47 over-expressed in multiple human cancers med-
iates the tumorigenesis.
The activation of MAP and PI-3 kinase pathways and the
effect of GIG47 knockdown on the cell invasion
To gain insight into the mechanism underlying the pro-
liferative and/or tumorigenic effect of human GIG47, we
examined the changes in signal transduction pathways.
Previous studies demonstrated that MAPK and PI3Kpathways are involved in mediating the function of a
neudesin, a mouse homologue of GIG47. A neudesin is
abundantly expressed in the developing brain and spinal
cord in mouse embryos. In addition, this protein exhibits
the significant neurotrophic activity in primary cultured
mouse neurons. Neudesin activated the mitogen-activated
protein (MAP) and phosphatidylinositol-3 (PI-3) kinase
pathways. This suggests that the neurotrophic activity
exerted by the neudesin is mediated via the activation of
the MAP and PI-3 kinases. Based on this, we, therefore,
analyzed the phosphorylation status of ERK and AKTs.
Total cellular proteins were extracted from cells over-
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and lysates were immunoblotted with specific phos-
phorylated antibodies (Figure 3A). We then found that
an increased phosphorylation of ERK and AKT was
observed in all three clones over-expressing GIG47 while
not in control cells. In contrast, GIG47 had no effect on
total ERK and AKT protein expression levels. This data
suggest that the tumorigenesis mechanism involving
GIG47 might be mediated by the activation of MAPK
and PI3K pathways.
To further investigate the role of GIG47 in tumori-
genecity, we performed the GIG47 knock-down experi-
ments. The baseline expression of GIG47 was determined
in a panel of human cancer cell lines as shown in
Figure 1E. The results showed that GIG47 was abun-
dantly expressed in most of human cancer cell lines. We
then examined the relative mRNA levels of GIG47 in
HeLa, MDA-MB-231, and A549 cells by real-time PCR
analysis. All three cell lines expressed high levels of
GIG47 in mRNA level (Figure 3B).Figure 3 The activation of MAP and PI-3 kinase pathways and the eff
prepared and quantified for protein content. A total of 100 μg protein was
specific antibodies against total or phosphorylated forms of ERK and AKT. I
mRNA levels were measured by real-time PCR. (C) Invasion analysis of MDA
performed in serum-rich medium (50% FBS). Experiments were repeated atTo determine whether GIG47 could be an effective
therapeutic target for the cancer, the effect of GIG47 on
cell tumorigenecity was examined. The efficacy of
GIG47 siRNA for knockdown of GIG47 mRNA was
confirmed by real-time PCR. We observed that GIG47
mRNA levels were significantly lowered in GIG47
siRNA-transfected cells (Figure 3B). The cell invasion
was determined in MDA-MB-231 cells transfected with
GIG47 siRNA. We then found that the down-regulation
of GIG47 expression inhibited the cell invasion in
MDA-MB-231 cells (Figure 3C). Therefore, all the data
support our conclusion that GIG47 over-expressed in
multiple human cancers mediates the tumorigenesis.
An overall structural analysis of GIG47 by CD and NMR
techniques
The native GIG47 is composed of 148 amino acid resi-
dues if we exclude the added solubilizing tags. The
structural determination of GIG47 might provide an
insight on the functional aspect as well as theect of GIG47 knockdown on the cell invasion. (A) Cell lysates were
resolved on 10% SDS-PAGE followed by immunoblot analysis with
mmunoblot for β-actin was done as a loading control. (B) GIG47
-MB-231 cells transfected with GIG47 siRNA and control siRNA was
least three times.
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structure prediction on GIG47 shows that this protein
contains some secondary structures (~23% helix and
~16% β-conformation by GOR4 predictor). The CD
spectrum of GIG47 shown in Figure 4A indicates that it
is mostly unstructured. When GIG47 is subjected to
GLOBPLOT [22], a program for predicting disordered
regions in intrinsically unfolded proteins (IUPs), ~ 60
out of 148 residues are predicted to be unstructured.
Similar disordered segments are predicted when GIG47
is analyzed by other IUP prediction programs.
In order to characterize the detailed conformational
features of GIG47 we produced an 15N/13 C double la-Figure 4 Overall structural analysis of GIG47 by CD and NMR techniq
sodium acetate (pH6.5), 0.1 mM PMSF, 0.01 mM EDTA, 1 mM DTT, 0.1 mM
indicates that the protein is mostly unstructured. (B) An 15 N-1 H HSQC spec
(pH 6.5), 0.1 mM PMSF, 0.01 mM EDTA, 1 mM DTT, 0.1 mM benzamidine, 0
indicated.multi-dimensional NMR techniques. A representative
15N-1H HSQC spectrum of GIG47 with assigned residues
is shown in Figure 4B. With the two solubility-enhancing
tags added to both termini of GIG47 the actual size of
protein studied by NMR is 208 residues long. Thus, res-
onance overlap prevented a complete resonance assign-
ment, but ~70% of GIG47 resonances could be assigned
at a reliable level (Additional file 1: Table S1).Determination of a high-resolution structure of GIG47
Secondary structure assignment was possible for the
assigned residues as shown in Figure 5A where chemicalues. (A) A CD spectrum of GIG47 (20 μM) obtained under 20 mM
benzamidine, 0.02% (w/v) NaN3 at 20°C. Low ellipticity at 220 nm
trum of GIG47 (500 μM) obtained under 20 mM sodium acetate-d3
.02% NaN3, 90% H2O/10%
2H2O at 30°C with assigned resonances
Figure 5 Secondary structure assignment and homology remodeling. (A) Chemical shift based secondary structure assignment in GIG47 and
1TOG. The overall secondary structure distribution determined by Cα chemical shifts in two proteins is very similar except for the additional
solubility tagging regions at the protein termini of GIG47. (B) The ribbon diagrams for GIG47 and 1TOG. The structure of GIG47 was obtained by
NMR chemical shifts and homology modeling using 1TOG as a template. The two structures are highly superimposable except for the additional
solubility tag regions at the protein termini of GIG47.
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log 1TOG [21] are displayed.
Shown in Figure 5B is the structure of GIG47 obtained
by a homology modeling calculation [20] using 1TOG as
a template. GIG47 consists of four α-helices (residues:
25–32, 55–58, 73–78, 95–112, denoted as α1 ~ α4) and
6 β-strands (residues: 23–24, 41–43, 48–50, 70–71,
115–117, 123–124, denoted as β1 ~ β6), arranged in a
β1-α1-β2-β3-α2-β4-α3-α4-β5-β6 topology. GIG47 has
two β-sheets: a short one consists of two β-strands
arranged in parallel fashion (β1 and β6 in N- and
C-terminal region, respectively) and the other consists
of four β-strands (β4, β2, β3, and β5). Among them,
β4 and β2 form a parallel β-sheet and β2, β3 and β5
form an antiparallel β-sheet. Three α-helices (α2, α3,
and α4) lying over the antiparallel β-sheet and loop
linking α2 with α3 form a wide pocket, which may
play a role of hydrophobic binding pocket.
The final structure of GIG47 protein obtained by a
combination of homology modeling calculation and
NMR chemical shift assisted secondary structure predic-
tion is similar to that of 1T0G. However, there are local
structural differences between GIG47 and 1TOG. First,GIG47 has longer helices involving 25E ~ 32 G and
95A~112 K than the corresponding helices (14A~ 17 L
and 84E~ 98E, respectively) in 1T0G. Second, a short
β-strand (β4) found in GIG47 is absent in 1TOG.
Third, a long β-strand, V103VGRVV108, located at the
C-terminal region of 1T0G are replaced by two short
β-strands, 115I ~ 117 G and 123I ~ 124 L in GIG47. Two
termini of GIG47 show disordered residues (22 and 23
residues at the N- and the C-terminus, respectively).
When combined with a 49-residue solubility-enhancing
tag inserted to the N-terminus of GIG47 the actual
GIG47 protein studied by NMR contains a 71 disordered
residues at its N-terminus.
Discussion
To discover genes involved in human breast carcinogen-
esis, we applied DDRT-PCR and identified the candidate
human breast cancer-related gene, GIG47 (GenBank ac-
cession number AY762102). GIG47 encodes neudesin, a
neuron derived neurotrophic factor (NENF) (GenBank
accession number NM_013349) in the database.
The neudesin gene has been identified in vertebrates
including humans, mice, and zebrafish, but not in
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specific to vertebrates. The human neudesin gene is
located on chromosome 1 at p33; however, this location
has not shown linkage with known inherited diseases
[6]. Neudesin is a novel secreted protein with essentially
no primary structural homology to any known proteins.
Its activity was governed by the activation of the MAP
and PI-3 kinase pathways possibly via the activation of a
Go/Giprotein-coupled receptor. Neudesin is therefore
assumed to be a novel neurotrophic factor with a unique
structure. Therefore, the study on neudesin may provide
new insights into the neuronal development and main-
tenance [6].
However, study demonstrated that GIG47 mRNA is
over-expressed in human immortalized cells [10]. In
addition, its protein was also detected as abundant
among estrogen receptor (ER)+/progesterone receptor
(PR) + breast cancers [11]. Nevertheless, it is unknown
how GIG47 contributes to the cellular and biochemicalFigure 6 Comparison of amino acid sequences of GIG47 and NENF an
heme-binding region. (A) Amino acid sequences of GIG47 (human neude
heme/steroid binding domain is shown in red. The three residues in bold a
GIG47 is shown with three potential heme-binding residues (Tyr58, Tyr64 a
domain is colored red. The blue regions in the ribbon indicate hydrophobi
clearly visible (indicated by an arrow) between two α-helices (α2 and α3).mechanisms of human tumorigenesis. In this study, our
result also revealed that GIG47 is over-expressed in vari-
ous human tumors including carcinomas of the uterine
cervix, lymphoma, colon, lung, skin and leukemia, as
well as carcinoma of the breast. In a sharp contrast, ex-
pression of GIG47 was generally low in diverse human
normal tissues. It implies that GIG47 may play an onco-
genic role in multiple body organs. In order to address
this, we took advantage of ectopic over-expression sys-
tem and demonstrated that GIG47, indeed, mediates the
tumorigenesis of human breast cancer by promoting the
invasiveness of breast cancer cells and tumor growth
in vivo. Therefore, this result strongly supports that
GIG47 plays a role in the human tumorigenesis.
Further understanding on GIG47 function and poten-
tially useful information for designing anti-cancer phar-
maceuticals may be provided by studying the structural
characteristics of GIG47 at an atomic resolution. GIG47
itself shows a poor solubility when it is expressed alone.d a ribbon diagram of GIG47 showing the potential
sin) and NENF (mouse neudesin) are aligned. The potential
re the putative heme-binding sites in NENF. (B) A ribbon diagram of
nd His98) displayed in a stick representation mode. The heme-binding
c residues. A potential heme/steroid binding hydrophobic pocket is
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enhancing tags, which made the total length of the ac-
tual protein studied by NMR to consist of 208 residues.
Consequently achieving a full resonance assignment was
not possible. Nevertheless, as the assigned region of
GIG47 has a strong sequence homology of ~50% to a
hypothetical protein At2g24940.1 from Arabidopsis
thaliana (1TOG) with an unknown function (Figure 5),
we were able to produce a high-resolution structure of
GIG47 by combining NMR chemical shift indices and
homology modeling process. Thus our structure deter-
mination of GIG47 incidentally made it possible to as-
sign function to a hypothetical protein with an
unknown function.
A structure-based rational drug design strategy in-
cluding SAR-by-NMR screening was successfully applied
in developing potent anti-cancer agents based upon in-
hibitory activity of mdm2 [23-26]. Since the potential
ligand-binding pocket in GIG47 is hydrophobic in na-
ture like that in mdm2, above strategy may also prove to
be useful in developing anti-cancer agents using inhibi-
tors against GIG47. A previous work on NENF (mouse
neudesin) showed that the protein has a heme/steroid
binding region (Leu22 ~Ala120) [7]. As shown in
Figure 6A, the amino acid sequences of NENF and
GIG47 are highly homologous (94.6%). In particular the
residues in the heme binding region of NENF are exactly
the same as those in GIG47 except for 4 residues. Thus
we expect that GIG47 (human neudesin) should be able
to form a heme/steroid binding region. Three residues
(Y58, Y64, H98) in mouse neudesin play an important
role in binding with heme. In order to determine poten-
tial heme-binding residues in GIG47 we have used the
prediction program, HemeBind [27], and found that
Phe57, Tyr58, Arg60, Tyr64, Ala66, and Leu67 in GIG47
may interact with heme. The structure of GIG47 we
have presented in this work reveal that two residues,
Tyr58 and Tyr64, are potential heme-binding sites as
shown in Figure 6B, where the side-chains of these two
tyrosines are located in the potential heme-binding
pocket facing toward the heme. A similar structural pat-
tern is observed in human adrenal inner zone antigen
(hIZA), which has a tetrapeptide segment (D99VTK102)
that anchors the heme into the hydrophobic pocket [28].
A similar tetrapeptide segment is found in GIG47,
D50VTS53, thus is expected to carry out a similar role of
anchoring a heme group into the hydrophobic pocket of
GIG47. In GIG47, a third potential heme-binding resi-
due [7], His98, is located in the opposite side of two Tyr
residues and therefore is not likely to contribute to heme
binding. The structural analysis described above for
GIG47 insinuates that progesterone, a steroid derived
from breast tumors, may be the cellular ligand for
GIG47.Conclusion
In conclusion, GIG47 is over-expressed in various
human tumors and plays an oncogenic role especially in
the breast cancer. Although further investigation is
needed, this result indicates that increased expression of
the GIG47 may be associated with human tumorigen-
esis. Therefore, GIG47 might be a good target for devel-
oping diagnostic and therapeutic agents against human
cancers when a detailed functional domain is identified
using the three-dimensional structure of GIG47 deter-
mined in this investigation.
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